Facchina

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company leverages its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. Its lead product, Ryoncil (remestemcel-L), received FDA approval in December 2024 for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. Mesoblast is also advancing rexlemestrocel-L for advanced chronic heart failure and chronic low back pain, both of which have completed Phase 3 trials. The company's business model focuses on transitioning from a clinical development stage to a revenue-generating commercial entity.